ARGX vs. GMAB: argenx vs. Genmab Stock Comparison

November 11, 2026

How do argenx (ARGX) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Genmab (GMAB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Both argenx (ARGX) and Genmab (GMAB) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Company profile comparison for argenx (ARGX) and Genmab (GMAB)
Profile Item	ARGX	GMAB
Name	argenx SE American Depositary Receipt	Genmab A/S American Depositary Shares
Country/Region	Netherlands	Denmark
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	58.31 billion USD	32.98 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	May 18, 2017	June 1, 2009
Security Type	ADR	ADR

Price Performance

Cumulative Growth

ARGX

GMAB

GSPC

argenx (ARGX) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for argenx (ARGX) and Genmab (GMAB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for argenx (ARGX) and Genmab (GMAB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
Total Return (1Y)	11.91%	91.17%
Total Return (3Y, Annualized)	25.68%	20.70%
Total Return (5Y, Annualized)	24.22%	3.98%

Risk Profile

Drawdown History

ARGX

GMAB

GSPC

argenx (ARGX) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for argenx (ARGX) and Genmab (GMAB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
Volatility (1Y, Annualized)	37.87%	45.68%
Beta (5Y)	0.45	0.72
Max Drawdown (5Y)	-38.20%	-61.79%
Avg. Volume (3M)	359.84K	4.09M

Risk-Adjusted Performance

Risk-Return Positioning

ARGX and GMAB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
Sharpe Ratio (1Y)	0.20	1.90
Sortino Ratio (1Y)	0.31	3.82

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Genmab (GMAB) earns 12.07% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ARGX: --

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max: 109.18%
GMAB: 12.07%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

argenx (ARGX) vs. Genmab (GMAB): ARGX does not report ROE, so it has no value marker; GMAB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

argenx (ARGX) at 31.73% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX: 31.73%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max: 18.05%
GMAB: 16.97%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

argenx (ARGX) vs. Genmab (GMAB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both argenx (ARGX) at 36.27% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max: 83.12%
ARGX: 36.27%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max: 83.12%
GMAB: 37.15%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

argenx (ARGX) vs. Genmab (GMAB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
ROE (TTM)	--	12.07%
ROA (TTM)	--	8.24%
Net Margin (TTM)	31.73%	16.97%
Operating Margin (TTM)	36.27%	37.15%
Gross Margin (TTM)	59.84%	92.67%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Genmab (GMAB) at 19.19% is closer to the peer norm — faster top-line expansion for ARGX.

argenx (ARGX) vs. Genmab (GMAB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both argenx (ARGX) at 53.13% and Genmab (GMAB) at -9.23% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

argenx (ARGX) vs. Genmab (GMAB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
Revenue Growth (YoY)	89.64%	19.19%
Revenue Growth (3Y CAGR)	116.25%	21.23%
EPS Growth (YoY)	53.13%	-9.23%
EPS Growth (3Y CAGR)	--	8.48%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Genmab (GMAB) shows current ratio of 2.45 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
ARGX: --

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
GMAB: 2.45
Min: 0.10

argenx (ARGX) vs. Genmab (GMAB): ARGX does not report current ratio, so it has no value marker; GMAB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Genmab (GMAB) at 0.82 sits in the higher-leverage quartile.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
ARGX: 0.01
Min: 0.00

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max: 1.42
GMAB: 0.82
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

argenx (ARGX) vs. Genmab (GMAB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
Current Ratio (MRQ)	--	2.45
Debt / Equity (MRQ)	0.01	0.82
Net Debt / EBITDA	-2.70	2.45

Dividends

Dividend Yield (TTM)

Neither argenx (ARGX) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. Genmab (GMAB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither argenx (ARGX) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. Genmab (GMAB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max: 85.34
Q3: 43.46
ARGX: 32.12
Median: 26.69
Q1: 13.30
Min: 0.07

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max: 85.34
GMAB: 45.84
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

argenx (ARGX) vs. Genmab (GMAB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max: 58.18
Q3: 25.77
ARGX: 9.86
Median: 7.30
Q1: 3.01
Min: 0.01

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max: 58.18
Q3: 25.77
GMAB: 7.68
Median: 7.30
Q1: 3.01
Min: 0.01

argenx (ARGX) vs. Genmab (GMAB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Genmab (GMAB) at 5.36 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX: 172.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max: 13.53
Q3: 6.54
GMAB: 5.36
Median: 3.25
Q1: 1.69
Min: -5.59

argenx (ARGX) vs. Genmab (GMAB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Genmab (GMAB)
Metric	ARGX	GMAB
P/E Ratio (TTM)	32.12	45.84
P/S Ratio (TTM)	9.86	7.68
P/B Ratio (MRQ)	172.23	5.36
Free Cash Flow Yield (TTM)	--	2.59%